|
|
GLA-SE |
|
Vaxjo ID |
163 |
|
Vaccine Adjuvant Name |
GLA-SE |
|
Adjuvant VO ID |
VO_0005420
|
|
Description |
TLR4 agonist glucopyranosyl lipid A (GLA) in a stable oil-in-water emulsion (SE) formulation that induces a Th1 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
GLA |
|
Storage |
2-8C |
|
Preparation |
stable oil in water emulsion |
|
Function |
innate immune activation |
| References |
(Soza, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=62]
Duthie et al., 2016: Duthie MS, Favila M, Hofmeyer KA, Tutterrow YL, Reed SJ, Laurance JD, Picone A, Guderian J, Bailor HR, Vallur AC, Liang H, Mohamath R, Vergara J, Howard RF, Coler RN, Reed SG. Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis. Vaccine. 2016; 34(25); 2779-2786. [PubMed: 27142329].
|
|
